CJC-1295 (No DAC)

CJC-1295 No DAC 5mg

CJC-1295 No DAC is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Unlike CJC-1295 with DAC (Drug Affinity Complex), this variant does not incorporate the DAC component, resulting in a shorter half-life. Researchers suggest that this design allows for controlled, pulsatile release patterns more closely resembling natural endogenous growth hormone secretion.

Overview

CJC-1295 No DAC is composed of 29 amino acids and is categorized as a tetrasubstituted GHRH analog. The modifications introduced to the amino acid sequence may enhance stability against enzymatic degradation compared to native GHRH. By interacting with GHRH receptors in the anterior pituitary, CJC-1295 No DAC is posited to stimulate growth hormone (GH) release, which in turn may lead to increased systemic and tissue-specific production of insulin-like growth factor 1 (IGF-1).

Studies indicate that the absence of DAC allows for a reduced circulation time compared to DAC-linked analogs, leading to shorter but more physiologically aligned elevations in GH. Researchers propose that this pulsatile stimulation may be favorable for experimental models requiring periodic GH spikes rather than sustained elevations.

Chemical Makeup

Molecular Formula: C152H252N44O42

Molecular Weight: 3367.9 g/mol

Other Known Titles: Modified GRF (1-29)

Appearance: White lyophilized powder

Purity: >98% (HPLC)

Solubility: Soluble in sterile water or mild acidic solutions

Storage: Stable at –20 °C; protect from light and moisture

Research and Clinical Studies

Growth Hormone Pulsatility

Research on CJC-1295 No DAC demonstrates its potential to increase pulsatile GH secretion without extending circulating half-life beyond a few hours. Investigators suggest that this property may support research into the role of GH rhythmicity in metabolic and regenerative pathways.

Metabolic Activity

Experimental models indicate that GH release stimulated by CJC-1295 No DAC may indirectly support increased IGF-1 production. IGF-1 is considered a primary mediator of GH activity, with suggested roles in tissue growth, protein synthesis, and inhibition of apoptosis. In parallel, GH itself is thought to promote lipolysis, particularly within adipose depots such as visceral fat.

Comparisons with CJC-1295 DAC

While CJC-1295 with DAC has been studied for its extended release profile and prolonged half-life, the No DAC variant is primarily utilized in research requiring acute, pulsatile exposure. This distinction allows investigators to evaluate differences between sustained and transient GH signaling across various metabolic and regenerative endpoints.

References

1. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne J-P, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. https://pubmed.ncbi.nlm.nih.gov/16368724/
   
2. Frohman LA, Kineman RD. Growth hormone-releasing hormone and pituitary development, hyperplasia and tumorigenesis. Trends Endocrinol Metab. 2002;13(8):299-303. https://pubmed.ncbi.nlm.nih.gov/12163226/
   
3. Jaffe CA, DeMott-Friberg R, Barkan AL. Endogenous growth hormone (GH)-releasing hormone is required for GH responses to pharmacological stimuli. J Clin Invest. 1996;97(4):934-940. https://pubmed.ncbi.nlm.nih.gov/8613546/
   
4. Veldhuis JD, Roemmich JN, Richmond EJ, et al. Endocrine control of body composition in infancy, childhood, and puberty. Endocr Rev. 2005;26(1):114-146. https://pubmed.ncbi.nlm.nih.gov/15689574/
   
5. Ho KK. GH deficiency in adulthood and the effects of GH replacement: a review. J Clin Endocrinol Metab. 1996;81(12):460-462. https://pubmed.ncbi.nlm.nih.gov/8964823/
   
6. Grinspoon S, Biller BM. Clinical review 62: Laboratory assessment of adrenal insufficiency. J Clin Endocrinol Metab. 1994;79(4):923-931. https://pubmed.ncbi.nlm.nih.gov/7962307/
   
7. Bowers CY. Synergistic effects of GHRP and GHRH analogs on GH release in vitro and in vivo. Peptides. 1998;19(5):877-888. https://pubmed.ncbi.nlm.nih.gov/9622012/
   
8. Chapman IM, Hartman ML, Pezzoli SS, et al. Pharmacokinetics and pharmacodynamics of a potent growth hormone-releasing peptide in healthy adults. J Clin Endocrinol Metab. 1996;81(12):4378-4383. https://pubmed.ncbi.nlm.nih.gov/8954040/
   
9. Veldhuis JD, Iranmanesh A, Ho KK, et al. Dual defects in pulsatile growth hormone secretion and clearance subserve the hyposomatotropism of obesity in man. J Clin Endocrinol Metab. 1991;72(1):51-59. https://pubmed.ncbi.nlm.nih.gov/1986010/